NasdaqGM:XENEBiotechs
Assessing Xenon Pharmaceuticals (XENE) Valuation After Positive Phase 3 X TOLE2 Azetukalner Results
Xenon Pharmaceuticals (XENE) has drawn fresh attention after reporting positive Phase 3 X TOLE2 results for azetukalner in focal onset seizures, followed closely by a US$650 million follow on equity offering.
See our latest analysis for Xenon Pharmaceuticals.
The latest clinical success and equity raise come after a strong run, with a 30 day share price return of 33.08% and a 1 year total shareholder return of 56.95%. This suggests momentum has been building around Xenon Pharmaceuticals as...